NCT04800172View on ClinicalTrials.gov

The Possible Effects of Roflumilast on Obesity Related Disorders

PHASE3CompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

May 1, 2021

Primary Completion Date

March 31, 2022

Study Completion Date

March 31, 2022

Conditions
ObesityPreDiabetes
Interventions
DRUG

Roflumilast

administration of roflumilast 500 mcg tablet once daily for 3 months.

DRUG

placebo

administration of placebo tablet once daily for 3 months.

Trial Locations (1)

Unknown

Sara Mohammad Zayed, Tanta

All Listed Sponsors
lead

Tanta University

OTHER